(GNW) Genworth Financial - Ratings and Ratios
Exchange: NYSE • Country: United States • Currency: USD • Type: Common Stock • ISIN: US37247D1063
GNW: Mortgage Insurance, Long-Term Care Insurance, Life Insurance, Annuities
Genworth Financial Inc. (NYSE:GNW) is a well-established player in the insurance industry, with a history dating back to 1871. Originally part of GE, it spun off in 2004 and is now headquartered in Richmond, Virginia. The company operates through three core segments: Enact, Long-Term Care Insurance, and Life and Annuities.
The Enact segment specializes in mortgage insurance, offering both private mortgage insurance for residential loans and pool insurance products. This segment is crucial as it provides coverage for prime-based, individually underwritten mortgages, mitigating risks for lenders.
The Long-Term Care Insurance segment addresses the growing need for coverage against escalating long-term care costs. This includes services provided in homes, assisted living facilities, and nursing homes. Despite its importance, this segment faces challenges due to high-risk exposure and actuarial complexities.
The Life and Annuities segment offers a range of products aimed at protection and retirement income. This includes various life insurance policies and fixed and variable annuities, providing customers with diverse financial protection options.
Genworth distributes its products through a mix of direct sales, in-house representatives, and digital marketing. Their approach ensures a broad reach and adaptability to market needs.
Financially, Genworth has a market cap of approximately $3.16 billion. Key metrics include a P/E ratio of 28.38, a P/B ratio of 0.38, and a P/S ratio of 0.43, indicating its current market valuation.
As an investor, understanding Genworths position in the insurance market, especially with an aging population, is key. Their focus on long-term care and mortgage insurance aligns with demographic trends, though the long-term care segments risks warrant careful consideration. Visit their website at https://www.genworth.com for more details.
Additional Sources for GNW Stock
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
GNW Stock Overview
Market Cap in USD | 2,791m |
Sector | Financial Services |
Industry | Insurance - Life |
GiC Sub-Industry | Life & Health Insurance |
IPO / Inception | 2004-05-25 |
GNW Stock Ratings
Growth 5y | 60.3% |
Fundamental | -24.4% |
Dividend | 5.71% |
Rel. Strength Industry | -17.1 |
Analysts | 3/5 |
Fair Price Momentum | 5.68 USD |
Fair Price DCF | 7.89 USD |
GNW Dividends
Dividend Yield 12m | 0.00% |
Yield on Cost 5y | % |
Annual Growth 5y | 0.00% |
Payout Consistency | 19.0% |
GNW Growth Ratios
Growth Correlation 3m | -52.5% |
Growth Correlation 12m | 82.2% |
Growth Correlation 5y | 90.2% |
CAGR 5y | 8.85% |
CAGR/Max DD 5y | 0.15 |
Sharpe Ratio 12m | 0.33 |
Alpha | -8.57 |
Beta | 0.92 |
Volatility | 52.87% |
Current Volume | 5023.1k |
Average Volume 20d | 4788.1k |
As of February 23, 2025, the stock is trading at USD 6.53 with a total of 5,023,119 shares traded.
Over the past week, the price has changed by -10.43%, over one month by -6.58%, over three months by -14.30% and over the past year by +7.76%.
Neither. Based on ValueRay Fundamental Analyses, Genworth Financial is currently (February 2025) neither a good nor a bad stock to buy. It has a ValueRay Fundamental Rating of -24.36 and therefor a neutral outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of GNW as of February 2025 is 5.68. This means that GNW is currently overvalued and has a potential downside of -13.02%.
Genworth Financial has received a consensus analysts rating of 3.00. Therefor, it is recommend to hold GNW.
- Strong Buy: 0
- Buy: 0
- Hold: 1
- Sell: 0
- Strong Sell: 0
According to ValueRays Forecast Model, GNW Genworth Financial will be worth about 6.5 in February 2026. The stock is currently trading at 6.53. This means that the stock has a potential upside of +0%.
Issuer | Forecast | Upside |
---|---|---|
Wallstreet Target Price | 8.5 | 30.2% |
Analysts Target Price | 8.5 | 30.2% |
ValueRay Target Price | 6.5 | 0% |